소화기 OTC 의약품 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약제 클래스별, 적응증별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Global Gastrointestinal OTC Drugs Market was valued at USD 41.50 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.15% through 2030. Gastrointestinal over the counter (OTC) drugs are medications that are available without a prescription and are designed to provide relief from a range of common gastrointestinal symptoms and conditions. These drugs are typically self-administered by consumers to alleviate discomfort and manage minor digestive issues. One of the primary advantages of gastrointestinal OTC drugs is their accessibility. Consumers can purchase these products without the need for a prescription, making them readily available at retail pharmacies, drug stores, supermarkets, and online platforms. OTC drugs are typically used as directed on the packaging or as advised by a healthcare professional. Gastrointestinal OTC drugs are considered safe and effective when used according to the labeled instructions. Their non-prescription status reflects their suitability for self-medication by individuals experiencing mild to moderate gastrointestinal symptoms. However, individuals with severe or chronic gastrointestinal conditions should seek guidance from a healthcare provider.

The global aging population is more susceptible to gastrointestinal issues. As people age, they are more likely to experience digestive problems, which increases the need for OTC gastrointestinal remedies. Increasing awareness among consumers about gastrointestinal health and related issues encourages them to seek OTC solutions for common digestive problems. Educational campaigns and information dissemination contribute to this awareness. Factors like poor dietary habits, stress, sedentary lifestyles, and irregular eating patterns contribute to gastrointestinal problems. These lifestyle factors drive the demand for OTC drugs to alleviate symptoms. OTC drugs offer a non-invasive and cost-effective means of managing common gastrointestinal issues. Many individuals prefer OTC options before considering prescription medications or medical procedures. Pharmaceutical companies continue to innovate by developing new formulations of OTC gastrointestinal drugs, such as fast-acting or long-lasting relief options, chewable tablets, and liquid formulations, to cater to consumer preferences.

Key Market Challenges

Generic Competition

Generic gastrointestinal OTC drugs typically cost less than their branded counterparts. This price competition can lead to lower profit margins for pharmaceutical companies that market branded OTC drugs, as consumers often opt for more affordable generic options. Some gastrointestinal OTC drugs have been on the market for a long time, and they may have multiple generic equivalents. This can lead to market saturation, with numerous generic products vying for a share of the market. When a branded OTC drug's patent expires, it opens the door for generic manufacturers to enter the market with their versions of the drug. As a result, the branded drug may experience a decline in market share. The presence of generic competitors can put pressure on branded OTC drug manufacturers to lower their prices, reducing their profitability. They may need to engage in price wars to maintain their market share. Generic drugs are generally perceived as cost-effective alternatives to branded drugs. This perception can lead consumers to switch from branded to generic OTC drugs when available, contributing to the challenges faced by branded manufacturers. Generic drugs must meet regulatory standards for safety, efficacy, and quality, just like branded drugs. Branded manufacturers may face increased scrutiny and competition from generic companies that adhere to these standards. Branded OTC drug manufacturers often invest heavily in marketing and promotional efforts to differentiate their products. However, generic competitors may not invest as much in marketing, relying on price advantage instead. When a branded OTC drug's patent protection or exclusivity period expires, it allows generic manufacturers to introduce their versions. This can lead to a rapid loss of market exclusivity for branded drugs.

Key Market Trends

Natural and Herbal Remedies

Many consumers prefer natural and herbal remedies for gastrointestinal problems because they perceive them as gentler and having fewer side effects compared to synthetic drugs. A growing awareness of holistic health and wellness has encouraged individuals to seek natural and herbal solutions to address the root causes of gastrointestinal issues rather than just managing symptoms. Natural and herbal OTC products often contain plant-based ingredients known for their digestive benefits. Examples include ginger, peppermint, chamomile, aloe vera, and licorice. Probiotic supplements and prebiotic fiber sources have gained popularity for promoting gut health. These products are often considered natural and may be incorporated into OTC gastrointestinal offerings. Homeopathic remedies using highly diluted natural substances are used by some consumers to address digestive discomfort and gastrointestinal conditions. Natural and herbal remedies are often associated with fewer adverse effects, making them appealing to individuals who want to avoid the potential side effects of synthetic medications. Manufacturers have expanded their product lines to include a wide variety of natural and herbal OTC options for different gastrointestinal symptoms, such as herbal teas, dietary supplements, and herbal extracts. Some natural and herbal OTC products combine multiple ingredients to target multiple aspects of gastrointestinal health. For example, a product may include both ginger and fennel to address digestive discomfort and bloating.

Key Market Players

• Viatris Inc.
• Sandoz Group AG
• Johnson & Johnson Services, Inc.
• Sun Pharmaceuticals Industries Limited
• Teva Pharmaceuticals Industries Ltd.
• Zydus Life science Ltd.
• Sanofi SA
• Bayer AG
• Pfizer Inc.
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastrointestinal OTC Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal OTC Drugs Market, By Drug Class:

• Laxatives
• Gastrointestinal Cancer Treatments
• Gastric Acid Reducers
• Anti-Diarrheal
• Proton Pump Inhibitors
• H2 Inhibitors
• Gastric Acid Neutralizers
• Bowel Anti-Inflammatory
• Anti-Emetics

Gastrointestinal OTC Drugs Market, By Indication:

• Gastroesophageal Reflux Disease or Heartburn
• Constipation
• Diarrhea
• Motion Sickness
• Others

Gastrointestinal OTC Drugs Market, By End User:

• Hospitals Pharmacies
• Retail Pharmacies
• Online pharmacies
• Others

Gastrointestinal OTC Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal OTC Drugs Market.

Available Customizations:

Global Gastrointestinal OTC Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal OTC Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics)
  • 5.2.2. By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, Others)
  • 5.2.3. By End User (Hospitals Pharmacies, Retail Pharmacies, Online pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Gastrointestinal OTC Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Gastrointestinal OTC Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. India Gastrointestinal OTC Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Gastrointestinal OTC Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Gastrointestinal OTC Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Indication
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Gastrointestinal OTC Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Indication
      • 6.3.5.2.3. By End User

7. Europe Gastrointestinal OTC Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Gastrointestinal OTC Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Gastrointestinal OTC Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Gastrointestinal OTC Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Gastrointestinal OTC Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Gastrointestinal OTC Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. North America Gastrointestinal OTC Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Gastrointestinal OTC Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Gastrointestinal OTC Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Gastrointestinal OTC Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User

9. South America Gastrointestinal OTC Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gastrointestinal OTC Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Gastrointestinal OTC Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Gastrointestinal OTC Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Gastrointestinal OTC Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gastrointestinal OTC Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Gastrointestinal OTC Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Gastrointestinal OTC Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Gastrointestinal OTC Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Viatris Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Sandoz Group AG
• 16.3. Johnson & Johnson Services, Inc.
• 16.4. Sun Pharmaceuticals Industries Limited
• 16.5. Teva Pharmaceuticals Industries Ltd.
• 16.6. Zydus Life science Ltd.
• 16.7. Sanofi SA
• 16.8. Bayer AG
• 16.9. Pfizer Inc.
• 16.10.GlaxoSmithKline Plc

17. Strategic Recommendations

18. About Us & Disclaimer